Sunder-Plassmann, V., Aksoy, O., Lind, J., Pecherstorfer, M., Vallet, S. & Podar, K., 2022. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: An early 2022 glance into the future. Expert Opinion on Pharmacotherapy.
Aksoy, O., Lind, J., Sunder-Plassmann, V., Pecherstorfer, M., Vallet, S. & Podar, K., 2021. Poster: P-082: Delineating CDK9- regulated molecular events for the development of rationally derived multiple myeloma treatment strategies. In 18th International Myeloma Workshop. 08.-11.09.2021. Vienna, Austria, S. S83-S84.
Lind, J., Vallet, S., Kollmann, K., Aksoy, O., Sunder-Plassmann, V., Zwickl-Traxler, E., Fan, F., Stoiber-Sakaguchi, D., Bakiri, L., Wagner, E., Sattler, M., Pecherstorfer, M. & Podar, K., 2021. Presentation: OAB-030: Combined targeting of distinct c-Myc and JunB transcriptional programs induces synergistic anti-myeloma activity. In 18th International Myeloma Workshop. 08.-11.09.2021. Vienna, Austria, S. S19-S20.
Aksoy, O., Lind, J., Sunder-Plassmann, V., Pecherstorfer, M., Vallet, S. & Podar, K., 2021. Delineating CDK9 Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies. Blood, 138(Supplement 1), S.1598-1598.
Lind, J., Vallet, S., Kollmann, K., Aksoy, O., Sunder-Plassmann, V., Fan, F., Zwickl-Traxler, E., Stoiber-Sakaguchi, D., Bakiri, L., Wagner, E.F., Sattler, M., Pecherstorfer, M. & Podar, K., 2021. Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity. Blood, 138(Supplement 1), S.2644-2644.